Skip to main
MRK

Merck (MRK) Stock Forecast & Price Target

Merck (MRK) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 22%
Buy 39%
Hold 39%
Sell 0%
Strong Sell 0%

Bulls say

Merck & Co is in a prime position to leverage its robust pipeline and established products to offset the potential loss of sales from Keytruda's LOE. The company's key therapeutic areas in oncology, cardiovascular disease, and infectious diseases, and its leading Animal Health business provide a diverse and resilient revenue stream. With a strong focus on research and development, and a track record of successful launches and acquisitions, Merck is well positioned for continued growth and potential outperformance in the market.

Bears say

Merck & Co is facing significant headwinds as several key drugs are expected to face patent expirations in the coming years, leading to potential loss in revenue. However, the company has announced topline results from a pivotal Phase 3 trial for an antiretroviral treatment, indicating potential for future growth. Additionally, the company's focus on combination strategies and new drug launches may help mitigate the impact of the LOE of Keytruda. However, concerns surrounding climate change, regulatory pressures, and compliance obligations represent material challenges to the business and its reputation.

Merck (MRK) has been analyzed by 18 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 39% recommend Buy, 39% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merck (MRK) Forecast

Analysts have given Merck (MRK) a Buy based on their latest research and market trends.

According to 18 analysts, Merck (MRK) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $125, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $125, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merck (MRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.